Breaking News Instant updates and real-time market news.

MIME

Mimecast

$43.21 /

+0.48 (+1.12%)

07:12
05/11/21
05/11
07:12
05/11/21
07:12

Mimecast appoints Bernd Leger as CMO

Mimecast Limited announced an executive appointment and chief technology and product officer search designed to support the company's strategy to accelerate innovation to serve customers and partners, expand the enterprise business, and sell integrated, multi-product offerings. Bernd Leger has been named chief marketing officer, effective May 17, 2021. Leger joins Mimecast from Nexthink, a leader in digital employee experience management software, where he served as chief marketing officer since 2019. In this newly created position, Leger will report directly to Peter Bauer, Mimecast's CEO. Mimecast will also bring together its product management and engineering organizations into a fully integrated team, led by a chief technology and product officer. The company has initiated a search to identify a chief technology and product officer with the assistance of Spencer Stuart, a leading executive search firm. In connection with this search, John Walsh, currently senior vice president, engineering and technical operations, and Christina Van Houten, currently chief strategy officer, will transition into advisory roles, effective May 31, 2021. Bauer will oversee the company's product management and engineering teams until a chief technology and product officer is identified.

  • 11

    May

MIME Mimecast
$43.21 /

+0.48 (+1.12%)

02/04/21
Mimecast price target lowered to $48 from $58 at BMO Capital
02/04/21
Mimecast price target lowered to $54 from $62 at Barclays
02/01/21 Stephens
Mimecast initiated with an Overweight at Stephens
01/15/21 Northland
Mimecast price target lowered to $70 from $77 at Northland

TODAY'S FREE FLY STORIES

Upgrade
Singapore Exchange upgraded to Overweight from Neutral at JPMorgan » 07:24
12/03/21
12/03
07:24
12/03/21
07:24
SPXCF

Singapore Exchange

$6.60 /

-0.02 (-0.30%)

JPMorgan analyst Harsh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPXCF Singapore Exchange
$6.60 /

-0.02 (-0.30%)

08/24/21 Credit Suisse
Singapore Exchange downgraded to Underperform from Neutral at Credit Suisse
08/22/21 Goldman Sachs
Singapore Exchange downgraded to Neutral from Buy at Goldman Sachs
Upgrade
OCBC upgraded to Overweight from Neutral at JPMorgan » 07:23
12/03/21
12/03
07:23
12/03/21
07:23
OVCHY

OCBC

$16.49 /

+0.25 (+1.54%)

JPMorgan analyst Harsh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OVCHY OCBC
$16.49 /

+0.25 (+1.54%)

04/06/21 Goldman Sachs
OCBC upgraded to Buy from Neutral at Goldman Sachs
03/10/21 JPMorgan
OCBC upgraded to Overweight from Neutral at JPMorgan
Initiation
International Container Terminal initiated with an Overweight at JPMorgan » 07:22
12/03/21
12/03
07:22
12/03/21
07:22
ICTEF

International Container Terminal Services

$3.90 /

+ (+0.00%)

JPMorgan analyst Shawn Ng…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Initiation
Cardiol Therapeutics initiated with a Buy at Canaccord » 07:22
12/03/21
12/03
07:22
12/03/21
07:22
CRDL

Cardiol Therapeutics

$2.02 /

+0.155 (+8.33%)

Canaccord analyst Edward…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRDL Cardiol Therapeutics
$2.02 /

+0.155 (+8.33%)

CRDL Cardiol Therapeutics
$2.02 /

+0.155 (+8.33%)

08/25/21 Raymond James
Cardiol Therapeutics price target raised to C$5 from C$4.50 at Raymond James
08/24/21 Raymond James
Raymond James ups Cardiol target to C$5 after FDA clears Phase II study
  • 03
    Nov
CRDL Cardiol Therapeutics
$2.02 /

+0.155 (+8.33%)

CRDL Cardiol Therapeutics
$2.02 /

+0.155 (+8.33%)

CRDL Cardiol Therapeutics
$2.02 /

+0.155 (+8.33%)

Recommendations
Citi opens 'positive catalyst watch' on Stellantis into software day » 07:21
12/03/21
12/03
07:21
12/03/21
07:21
STLA

Stellantis

$18.15 /

+0.455 (+2.57%)

Citi analyst Gabriel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
STLA Stellantis
$18.15 /

+0.455 (+2.57%)

STLA Stellantis
$18.15 /

+0.455 (+2.57%)

11/29/21 Citi
Stellantis resumed with a Buy at Citi
11/02/21 Nomura
Nomura downgrades Ford to Reduce, calls premium valuation 'hard to justify'
09/07/21 KeyBanc
Jeep micro site on Amazon points to auto sales moving online, says KeyBanc
09/03/21 Deutsche Bank
Stellantis deal 'significant opportunity' for Open Lending, says Deutsche Bank
STLA Stellantis
$18.15 /

+0.455 (+2.57%)

STLA Stellantis
$18.15 /

+0.455 (+2.57%)

STLA Stellantis
$18.15 /

+0.455 (+2.57%)

Downgrade
TopBuild downgraded to Neutral from Buy at BTIG » 07:19
12/03/21
12/03
07:19
12/03/21
07:19
BLD

TopBuild

$276.83 /

+12.445 (+4.71%)

BTIG analyst Ryan Gilbert…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BLD TopBuild
$276.83 /

+12.445 (+4.71%)

BLD TopBuild
$276.83 /

+12.445 (+4.71%)

11/03/21 Truist
TopBuild price target raised to $300 from $253 at Truist
10/21/21 BTIG
TopBuild price target raised to $292 from $271 at BTIG
09/10/21 JPMorgan
TopBuild price target raised to $264 from $246 at JPMorgan
09/09/21
Fly Intel: Top five analyst upgrades
BLD TopBuild
$276.83 /

+12.445 (+4.71%)

Downgrade
DocuSign downgraded to Hold from Buy at Needham » 07:18
12/03/21
12/03
07:18
12/03/21
07:18
DOCU

DocuSign

/

+

Needham analyst Scott…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DOCU DocuSign
/

+

DOCU DocuSign
/

+

07:08 Today Baird
DocuSign price target lowered to $220 from $330 at Baird
06:36 Today Wedbush
DocuSign downgraded to Neutral from Outperform at Wedbush
06:36 Today JMP Securities
DocuSign price target lowered to $307 from $320 at JMP Securities
06:17 Today Citi
DocuSign price target lowered to $231 from $389 at Citi
DOCU DocuSign
/

+

DOCU DocuSign
/

+

DOCU DocuSign
/

+

DOCU DocuSign
/

+

Recommendations
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald » 07:18
12/03/21
12/03
07:18
12/03/21
07:18
CRVS

Corvus Pharmaceuticals

$3.31 /

+0.05 (+1.53%)

, AZN

AstraZeneca

$54.78 /

-0.1 (-0.18%)

Cantor Fitzgerald analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$3.31 /

+0.05 (+1.53%)

AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

CRVS Corvus Pharmaceuticals
$3.31 /

+0.05 (+1.53%)

12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
09/22/21 Roth Capital
Corvus recent rally due to AstraZeneca data, says Roth Capital
08/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald
08/03/21 Mizuho
Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
11/22/21 Bryan Garnier
AstraZeneca downgraded to Buy from Conviction Buy at Bryan Garnier
10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
CRVS Corvus Pharmaceuticals
$3.31 /

+0.05 (+1.53%)

AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

  • 12
    Feb
AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

CRVS Corvus Pharmaceuticals
$3.31 /

+0.05 (+1.53%)

AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

CRVS Corvus Pharmaceuticals
$3.31 /

+0.05 (+1.53%)

AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

Upgrade
Citi upgrades Upstart to Buy on resumption after 55% selloff » 07:18
12/03/21
12/03
07:18
12/03/21
07:18
UPST

Upstart

$176.65 /

-3.1 (-1.72%)

Citi analyst Peter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UPST Upstart
$176.65 /

-3.1 (-1.72%)

UPST Upstart
$176.65 /

-3.1 (-1.72%)

07:05 Today Citi
Upstart upgraded to Buy from Neutral at Citi
11/10/21 Piper Sandler
Upstart should be bought on earnings selloff, says Piper Sandler
10/26/21
Fly Intel: Top five analyst downgrades
10/26/21 Jefferies
Jefferies downgrades Upstart to Hold, doubles target to $330
UPST Upstart
$176.65 /

-3.1 (-1.72%)

  • 16
    Jun
  • 09
    Apr
  • 16
    Dec
UPST Upstart
$176.65 /

-3.1 (-1.72%)

UPST Upstart
$176.65 /

-3.1 (-1.72%)

Hot Stocks
Hagerty to begin trading on NYSE on December 3 » 07:17
12/03/21
12/03
07:17
12/03/21
07:17
HGTY

Hagerty

$10.89 /

+0.735 (+7.24%)

, ADF

Aldel Financial

/

+

Hagerty (HGTY) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HGTY Hagerty
$10.89 /

+0.735 (+7.24%)

ADF Aldel Financial
/

+

Recommendations
Marvell price target raised to $98 from $85 at BMO Capital » 07:14
12/03/21
12/03
07:14
12/03/21
07:14
MRVL

Marvell

$71.02 /

+0.18 (+0.25%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

07:10 Today Goldman Sachs
Goldman admits to being wrong to stay on sidelines, upgrades Marvell to Buy
07:06 Today Goldman Sachs
Marvell upgraded to Buy from Neutral at Goldman Sachs
06:49 Today UBS
Marvell price target raised to $95 from $87 at UBS
06:38 Today Credit Suisse
Marvell price target raised to $105 from $85 at Credit Suisse
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

Recommendations
Kroger price target raised to $41 from $39 at BMO Capital » 07:11
12/03/21
12/03
07:11
12/03/21
07:11
KR

Kroger

$44.61 /

+4.4 (+10.94%)

BMO Capital analyst Kelly…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KR Kroger
$44.61 /

+4.4 (+10.94%)

KR Kroger
$44.61 /

+4.4 (+10.94%)

06:43 Today Deutsche Bank
Kroger price target raised to $45 from $43 at Deutsche Bank
06:28 Today Citi
Kroger price target raised to $47 from $43 at Citi
06:14 Today Barclays
Kroger price target raised to $38 from $37 at Barclays
11/03/21 Loop Capital
Loop Capital cuts Bed Bath & Beyond to Sell, cites deterioration in relevance
KR Kroger
$44.61 /

+4.4 (+10.94%)

KR Kroger
$44.61 /

+4.4 (+10.94%)

KR Kroger
$44.61 /

+4.4 (+10.94%)

KR Kroger
$44.61 /

+4.4 (+10.94%)

Hot Stocks
Xenon Pharmaceuticals presents additional data from Phase 2b X-TOLE trial » 07:10
12/03/21
12/03
07:10
12/03/21
07:10
XENE

Xenon Pharmaceuticals

$25.89 /

+0.065 (+0.25%)

Xenon Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$25.89 /

+0.065 (+0.25%)

XENE Xenon Pharmaceuticals
$25.89 /

+0.065 (+0.25%)

11/11/21 SVB Leerink
Xenon Pharmaceuticals price target raised to $40 from $34 at SVB Leerink
10/28/21 RBC Capital
Xenon Pharmaceuticals initiated with an Outperform at RBC Capital
10/06/21 Wedbush
Wedbush remains bullish on Xenon as financing gives firepower to advance XEN1101
10/04/21 Jefferies
Jefferies ups Xenon target to $50 after 'home run' epilepsy data
XENE Xenon Pharmaceuticals
$25.89 /

+0.065 (+0.25%)

  • 06
    Oct
  • 10
    Mar
XENE Xenon Pharmaceuticals
$25.89 /

+0.065 (+0.25%)

Upgrade
Goldman admits to being wrong to stay on sidelines, upgrades Marvell to Buy » 07:10
12/03/21
12/03
07:10
12/03/21
07:10
MRVL

Marvell

$71.02 /

+0.18 (+0.25%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

07:06 Today Goldman Sachs
Marvell upgraded to Buy from Neutral at Goldman Sachs
06:49 Today UBS
Marvell price target raised to $95 from $87 at UBS
06:38 Today Credit Suisse
Marvell price target raised to $105 from $85 at Credit Suisse
06:36 Today Citi
Marvell price target raised to $87 from $70 at Citi
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

Recommendations
Veeva price target lowered to $310 from $349 at Baird » 07:10
12/03/21
12/03
07:10
12/03/21
07:10
VEEV

Veeva

$262.17 /

-10.09 (-3.71%)

Baird analyst Joe Vruwink…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VEEV Veeva
$262.17 /

-10.09 (-3.71%)

VEEV Veeva
$262.17 /

-10.09 (-3.71%)

12/02/21 Needham
Veeva price target lowered to $327 from $385 at Needham
12/02/21 Baird
Veeva price target lowered to $310 from $349 at Baird
12/02/21 UBS
Veeva price target lowered to $290 from $320 at UBS
10/01/21 Stifel
Veeva assumed with a Buy at Stifel
VEEV Veeva
$262.17 /

-10.09 (-3.71%)

VEEV Veeva
$262.17 /

-10.09 (-3.71%)

VEEV Veeva
$262.17 /

-10.09 (-3.71%)

Recommendations
DocuSign price target lowered to $220 from $330 at Baird » 07:08
12/03/21
12/03
07:08
12/03/21
07:08
DOCU

DocuSign

$233.83 /

+2.77 (+1.20%)

Baird analyst William…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

06:36 Today Wedbush
DocuSign downgraded to Neutral from Outperform at Wedbush
06:36 Today JMP Securities
DocuSign price target lowered to $307 from $320 at JMP Securities
06:17 Today Citi
DocuSign price target lowered to $231 from $389 at Citi
04:47 Today Piper Sandler
DocuSign downgraded to Neutral from Overweight at Piper Sandler
DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

Hot Stocks
Aclaris Therapeutics publishes preclinical research on zunsemetinib » 07:06
12/03/21
12/03
07:06
12/03/21
07:06
ACRS

Aclaris Therapeutics

$12.64 /

+0.07 (+0.56%)

Aclaris Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ACRS Aclaris Therapeutics
$12.64 /

+0.07 (+0.56%)

ACRS Aclaris Therapeutics
$12.64 /

+0.07 (+0.56%)

07/23/21 Jefferies
Aclaris Therapeutics assumed with a Buy at Jefferies
06/16/21 H.C. Wainwright
Aclaris Therapeutics price target raised to $50 from $40 at H.C. Wainwright
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Piper Sandler
Aclaris Therapeutics initiated with an Overweight at Piper Sandler
ACRS Aclaris Therapeutics
$12.64 /

+0.07 (+0.56%)

  • 10
    Jun
  • 20
    Jan
ACRS Aclaris Therapeutics
$12.64 /

+0.07 (+0.56%)

Upgrade
Marvell upgraded to Buy from Neutral at Goldman Sachs » 07:06
12/03/21
12/03
07:06
12/03/21
07:06
MRVL

Marvell

$71.02 /

+0.18 (+0.25%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

06:49 Today UBS
Marvell price target raised to $95 from $87 at UBS
06:38 Today Credit Suisse
Marvell price target raised to $105 from $85 at Credit Suisse
06:36 Today Citi
Marvell price target raised to $87 from $70 at Citi
06:10 Today Deutsche Bank
Marvell price target raised to $100 from $76 at Deutsche Bank
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

Recommendations
GMS Inc. price target raised to $68 from $62 at Baird » 07:05
12/03/21
12/03
07:05
12/03/21
07:05
GMS

GMS Inc.

$57.74 /

+1.36 (+2.41%)

Baird analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GMS GMS Inc.
$57.74 /

+1.36 (+2.41%)

GMS GMS Inc.
$57.74 /

+1.36 (+2.41%)

06:14 Today Barclays
GMS Inc. price target raised to $61 from $56 at Barclays
09/08/21 Barclays
GMS Inc. price target raised to $56 from $49 at Barclays
09/03/21 Truist
GMS Inc. price target raised to $62 from $52 at Truist
09/03/21 Baird
GMS Inc. price target raised to $62 from $58 at Baird
GMS GMS Inc.
$57.74 /

+1.36 (+2.41%)

GMS GMS Inc.
$57.74 /

+1.36 (+2.41%)

Upgrade
Upstart upgraded to Buy from Neutral at Citi » 07:05
12/03/21
12/03
07:05
12/03/21
07:05
UPST

Upstart

$176.65 /

-3.1 (-1.72%)

Citi analyst Peter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UPST Upstart
$176.65 /

-3.1 (-1.72%)

UPST Upstart
$176.65 /

-3.1 (-1.72%)

11/10/21 Piper Sandler
Upstart should be bought on earnings selloff, says Piper Sandler
10/26/21
Fly Intel: Top five analyst downgrades
10/26/21 Jefferies
Jefferies downgrades Upstart to Hold, doubles target to $330
10/26/21 Jefferies
Upstart downgraded to Hold from Buy at Jefferies
UPST Upstart
$176.65 /

-3.1 (-1.72%)

  • 16
    Jun
  • 09
    Apr
  • 16
    Dec
UPST Upstart
$176.65 /

-3.1 (-1.72%)

UPST Upstart
$176.65 /

-3.1 (-1.72%)

Hot Stocks
Limbach Holding acquires Jake Marshall for $20M in cash » 07:05
12/03/21
12/03
07:05
12/03/21
07:05
LMB

Limbach Holding

$6.53 /

-0.32 (-4.67%)

Limbach Holding announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LMB Limbach Holding
$6.53 /

-0.32 (-4.67%)

LMB Limbach Holding
$6.53 /

-0.32 (-4.67%)

08/13/21 Lake Street
Limbach Holding price target raised to $21 from $19 at Lake Street
03/05/21
Fly Intel: Top five analyst initiations
03/05/21 Lake Street
Limbach Holding initiated with a Buy at Lake Street
LMB Limbach Holding
$6.53 /

-0.32 (-4.67%)

  • 11
    Feb
LMB Limbach Holding
$6.53 /

-0.32 (-4.67%)

Hot Stocks
Amicus announces EMA validated MAA for AT-GAA » 07:04
12/03/21
12/03
07:04
12/03/21
07:04
FOLD

Amicus

$11.13 /

+0.385 (+3.58%)

Amicus Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FOLD Amicus
$11.13 /

+0.385 (+3.58%)

FOLD Amicus
$11.13 /

+0.385 (+3.58%)

11/15/21 Stifel
Amicus upgraded to Buy from Hold at Stifel
09/30/21
Fly Intel: Top five analyst upgrades
09/30/21 Cowen
Amicus spin-out and profit potential makes it takeout target, says Cowen
09/30/21 JPMorgan
Amicus upgraded to Overweight from Neutral at JPMorgan
FOLD Amicus
$11.13 /

+0.385 (+3.58%)

FOLD Amicus
$11.13 /

+0.385 (+3.58%)

Initiation
Baird start Vor Biopharma with an Outperform ahead of AML data » 07:04
12/03/21
12/03
07:04
12/03/21
07:04
VOR

Vor Biopharma

$13.08 /

+1.71 (+15.04%)

As reported previously,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VOR Vor Biopharma
$13.08 /

+1.71 (+15.04%)

VOR Vor Biopharma
$13.08 /

+1.71 (+15.04%)

12/02/21 Baird
Vor Biopharma initiated with an Outperform at Baird
12/01/21 Oppenheimer
Vor Biopharma initiated with an Outperform at Oppenheimer
10/19/21 JMP Securities
Vor Biopharma initiated with an Outperform at JMP Securities
07/08/21 Stifel
Vor Biopharma, Janssen collaboration benefits both parties, says Stifel
VOR Vor Biopharma
$13.08 /

+1.71 (+15.04%)

  • 05
    Feb
Hot Stocks
BioCryst reports inducement grants under Nasdaq listing rule » 07:04
12/03/21
12/03
07:04
12/03/21
07:04
BCRX

BioCryst

$11.86 /

+0.58 (+5.14%)

BioCryst Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BCRX BioCryst
$11.86 /

+0.58 (+5.14%)

BCRX BioCryst
$11.86 /

+0.58 (+5.14%)

11/22/21 Piper Sandler
BioCryst financing lifts one of two overhangs, says Piper Sandler
11/04/21 Barclays
BioCryst price target lowered to $17 from $21 at Barclays
11/03/21 Piper Sandler
BioCryst earnings pullback a buying opportunity, says Piper Sandler
08/06/21 Jefferies
BioCryst downgraded to Hold from Buy at Jefferies
BCRX BioCryst
$11.86 /

+0.58 (+5.14%)

  • 11
    Aug
BCRX BioCryst
$11.86 /

+0.58 (+5.14%)

BCRX BioCryst
$11.86 /

+0.58 (+5.14%)

Recommendations
Ooma price target raised to $27 from $26 at Alliance Global Partners » 07:03
12/03/21
12/03
07:03
12/03/21
07:03
OOMA

Ooma

$19.05 /

+0.23 (+1.22%)

Alliance Global Partners…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OOMA Ooma
$19.05 /

+0.23 (+1.22%)

OOMA Ooma
$19.05 /

+0.23 (+1.22%)

09/03/21 B. Riley
Ooma price target raised to $27.50 from $24 at B. Riley
09/03/21 Benchmark
Ooma price target raised to $30 from $27 at Benchmark
09/03/21 JMP Securities
Ooma price target raised to $27 from $22 at JMP Securities
05/27/21 B. Riley
Ooma price target raised to $24 from $23.50 at B. Riley
OOMA Ooma
$19.05 /

+0.23 (+1.22%)

OOMA Ooma
$19.05 /

+0.23 (+1.22%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.